Skip to content

Probiotic and Prebiotic Supplementation in Elite Athletes with Spinal Cord Injury

The Effect of Probiotic and Prebiotic Supplementation on Gastrointestinal Comfort in Elite Athletes with Spinal Cord Injury: a Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04659408
Enrollment
14
Registered
2020-12-09
Start date
2021-03-01
Completion date
2021-10-29
Last updated
2024-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injuries

Keywords

probiotic supplementation, prebiotic supplementation

Brief summary

The main objective of this pilot study is to obtain information, which will be used for the design of a main randomized controlled trial (RCT) with a larger size based on feasibility, validity and sample size estimation as well as the potential effects of pre- and probiotic intake on intestinal microbiota. A larger trial will then be designed to test the hypothesis that adding probiotics or prebiotics may improve gut microbiome composition, gastrointestinal symptoms as well as cardiometabolic health indices in mid-term and possibly lead to improved sports performance over a longer-term period in athletes with a Spinal Cord Injury.

Detailed description

In this pilot crossover randomized controlled trial, twenty (N = 20) para-athletes will participate in an intervention consisting of a four-week intake of probiotic, using the commercially available multistrain probiotic preparation BactoSan pro FOS from Mepha (Basel, Switzerland), followed by a four-week wash-out period, and a four-week prebiotic intervention using Naturaplan Bio Oat Bran (Coop, Switzerland). Total duration of the study will be 16 weeks.

Interventions

DIETARY_SUPPLEMENTMultistrain probiotic preparation

One sachet daily, containing 3 grams of the freeze-dried multispecies probiotic Bactosan for a period of four weeks. One sachet will be mixed with 50-100 ml water and taken daily before breakfast or dinner. Bactosan contains the following eight bacterial strains: Bifidobacterium lactis W51, Bifidobacterium lactis W52, Enterococcus faecium W54, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Lactobacillus plantarum W21, Lactobacillus salivarius W24 and Lactococcus lactis W19, with a total viable cell count of 1 × 109 cfu/gram, and therefore 3 × 109 cfu/daily dose.

DIETARY_SUPPLEMENTOat Bran

5 grams (one teaspoon) daily of the oat bran together with a meal of preference. The oat bran can be added to the usual breakfast cereal, yoghurt, pancakes, juice, milk, salad sauce or in an omelette.

Sponsors

Swiss Paraplegic Research, Nottwil
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Randomized controlled trial with within-participants crossover

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* athletes with a spinal cord injury shortlisted as potential participants for major international events, such as the Paralympic Games 2021 in Tokyo and World Championship qualification

Exclusion criteria

* Chronic inflammatory bowel diseases (i.e. ulcerative colitis, Crohn's disease) * Taking antibiotics and/or other medication to alleviate gastrointestinal complaints at recruitment time point * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Recruitment rateAt baselineProportion of invited participants who agreed to participate in the trial
Dropout rateThrough study completion, an average of 4 monthsThe proportion of randomized participants who did not complete the study protocol
Severe adverse eventsThrough study completion, an average of 4 monthsThe occurrence of severe adverse events (SAEs)

Secondary

MeasureTime frameDescription
Loss of training days due to injury or illnessAt 0, 1, 2, 3 monthsAssessed using the Oslo Sports Trauma Research Centre (OSTRC) Overuse Injury Questionnaire, which consists of several multiple choice and open questions (no scale).
Gastrointestinal problemsAt 0, 1, 2, 3 monthsAssessed using the Gastrointestinal Quality of Life Index (GIQLI) of Eypasch, using a 5-point scale (0-4) with total range 0-144 and higher scores indicating better outcomes.
Recording of leisure time activityAt 0, 1, 2, 3 monthsAssessed using the Leisure Time Physical Activity Questionnaire (LTPA-Q), which records number of days and minutes of physical activity (no scale).
Food intake during three daysAt 0, 1, 2, 3 monthsSelf-reported intake (content and quantity) of food on a data sheet, including photo's. Calculations of the nutritional quality and quantity of consumed foods, drinks and nutritional supplements will be performed using PRODI® Swiss, a computer program for nutritional counselling and nutritional therapy.
Stool microbiome characterizationAt 0, 1, 2, 3 monthsStool probes will be sampled by the participants at home and send to the study center. The What's in my Pot? (WIMP) workflow (Oxford Nanopore Technologies) will be used to classify and identify species in real time, generating a graphical WIMP report of the sample composition and the most reliable placement in the taxonomy tree, assigning a score to each taxonomic placement.
Monitoring of inflammationAt 0, 1, 2, 3 monthsC-reactive protein (CRP) from blood samples in mg/L

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026